Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907936 | 0.87 | LTA4H (0.41) | CA4LTA4HTSHRKCNA3CHRNB2 | |
| SCHEMBL4456043 | 0.81 | LTA4H (0.41) | CA4LTA4HTSHRKCNA3CHRNB2 | |
| SCHEMBL1726379 | 0.80 | CA4 (0.42) | CA4LTA4HTSHRKCNA3CHRNB2 | |
| SCHEMBL8902684 | 0.79 | LTA4H (0.43) | CA4LTA4HTSHRKCNA3LMNA | |
| SCHEMBL4451586 | 0.78 | LTA4H (0.47) | CA4LTA4HKCNA3LMNAHTR1B | |
| Hydrochloric Acid SCHEMBL25265550 | 0.76 | ACHE (0.42) | TSHRL3MBTL1LMNAALDH1A1 | |
| SCHEMBL17198448 | 0.76 | LTA4H (0.39) | CA4LTA4HTSHRKCNA3CHRNB2 | |
| Bromide SCHEMBL25197194 | 0.76 | ACHE (0.42) | TSHRL3MBTL1LMNAALDH1A1 | |
| SCHEMBL29193843 | 0.76 | ACHE (0.52) | L3MBTL1LMNAALDH1A1 | |
| SCHEMBL4458129 | 0.75 | ALDH1A1 (0.44) | CA4LTA4HTSHRKCNA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0534388-A1 | Tungsten-imido catalysts for ring-opening metathesis polymerization of cycloolefins | HERCULES INCORPORATED (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0010565-B1 | PROCESS FOR PREPARING N-TRITYLIMIDAZOLE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-11-10 | — | — | EP | claimed |
| US-4242479-A | CATALYST OF ALUMINUM TRIHALIDE, ORGANOSILOXANE COMPOUND OR ETHER, MAGNESIUM ALCOHOLATE, TITANIUM-HALOGEN AND ORGANOALUMINUM COMPOUNDS | SHOWA YUKA KABUSHIKI KAISHA (JP) | 1980-12-30 | — | — | US | claimed |
| US-4216333-A | Process for preparing N-tritylimidazole compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-08-05 | — | — | US | claimed |
| EP-0010565-A1 | Process for preparing N-tritylimidazole compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-05-14 | — | — | EP | claimed |
| US-4045417-A | POLYMERIZATION IN PRESENCE OF A TERTIARY AMINE, A PHOSPHORUS COMPOUND, AND A METAL HALIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-08-30 | — | — | US | claimed |
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-117098749-A | [11C] Labeled acyclic retinoids, central nervous system activators and methods for their manufacture | 国立研究开发法人国立长寿医疗研究中心 | 2023-11-21 | — | — | CN | disclosed |
| US-20230365726-A1 | PROCESS FOR PREPARING HIGH-REACTIVITY ISOBUTENE HOMO- OR COPOLYMERS | BASF SE (DE) | 2023-11-16 | — | — | US | disclosed |
| EP-4249058-A1 | [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | National Center for Geriatrics and Gerontology (JP) | 2023-09-27 | — | — | EP | disclosed |
| CN-111518145-B | Cyano-bridged metal organic compound with intramolecular magnetic transformation and preparation method and application thereof | 荆楚理工学院 | 2023-06-20 | — | — | CN | disclosed |
| EP-4192887-A1 | PROCESS FOR PREPARING HIGH-REACTIVITY ISOBUTENE HOMO- OR COPOLYMERS | BASF SE (DE) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022107865-A1 | [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | 国立研究開発法人国立長寿医療研究センター | 2022-05-27 | — | — | WO | disclosed |
| US-4180636-A | MAGNESIUM HALIDE, TITANIUM COMPOUND ELECTRON DONOR COMPOUND, TRIALKYL ALUMINUM CATALYST | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1979-12-25 | — | — | US | disclosed |
| US-4125540-A | WITH ORGANO-PHOSPHORUS COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1978-11-14 | — | — | US | disclosed |
| US-4118374-A | PHOSPHITE, TERTIARY AMINE, LITHIUM OR CALCIUM HALIDE IN N-METHYLPYRROLIDONE OR DIMETHYLACETAMIDE AS POLYCONDENSATION SOLVENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1978-10-03 | — | — | US | disclosed |
| US-4087411-A | TRIOXANE, BORON FLUORIDE-TYPE CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JA) | 1978-05-02 | — | — | US | disclosed |
| US-4045417-A | POLYMERIZATION IN PRESENCE OF A TERTIARY AMINE, A PHOSPHORUS COMPOUND, AND A METAL HALIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-08-30 | — | — | US | disclosed |
| US-4028481-A | ACTIVATED TITANIUM TRICHLORIDE AND AN ORGANOALUMINUM COMPOUND | MITSUI TOATSU CHEMICALS, INCORPORATED (JA) | 1977-06-07 | — | — | US | disclosed |
| US-3992456-A | BY REACTING BUTADIENE WITH WATER IN THE PRESENCE OF A PALLADIUM CATALYST | UNION CARBIDE CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NR2E3, FABP7, RARB | CA4 2189/4885LTA4H 3621/4885TSHR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.